ResMed grows sales and profits

Sleep apnea treatment company ResMed (ASX: RMD) achieved strong growth in revenue and profit in the first quarter of the 2020 financial year driven by product innovation and increasing software sales. The Sydney company reported revenue up 16 per cent to $999.3 million (US$681 million) with net operating profit up 19 per cent. ResMed manufactures…